Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study

Overview of attention for article published in Journal of Clinical Oncology, March 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 6 news outlets
blogs: 1 blog
twitter: 68 X users

patent: 6 patents
reddit: 1 Redditor

Readers on

mendeley: 109 Mendeley

So far, Altmetric has seen 81 X posts from 68 X users, with an upper bound of 253,201 followers.

@RNA_Biotech @Getoutofmyway1 Final results: TP53-mutant patients, 40% achieved CR with median OS of 16.3 months. Thirty-four patients (36%) had allogeneic stem-cell transplant with 77% 2-year OS. https://t.co/9fgd6mexNR

RT @Wang_Yu_Hung: Magrolimab + Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes https://t.co/Oj90eERGmC #MDSsm @JCO_ASCO…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 77 additional X posts.